We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

43 hedge funds and large institutions have $40M invested in CTI BioPharma Corp. (DE) Common Stock in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

19% more capital invested

Capital invested by funds: $33.7M → $40M (+$6.28M)

13% more funds holding

Funds holding: 38 → 43 (+5)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
43
Holders Change
+5
Holders Change %
+13.16%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
8
Increased
9
Reduced
10
Closed
3
Calls
$34K
Puts
–
Net Calls
+$34K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$188K
2
PP
Paloma Partners
Connecticut
+$32K
3
Millennium Management
Millennium Management
New York
+$25.4K
4
HF
HRT Financial
New York
+$20.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$18.7K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$2.5M
2
Creative Planning
Creative Planning
Kansas
-$39.6K
3
Citadel Advisors
Citadel Advisors
Florida
-$27K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$19K
5
Northern Trust
Northern Trust
Illinois
-$16.8K

CTIC Hedge Fund Activity: Q2 2020 in Review

43 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2020, worth a combined $40M — up 19% from $33.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CTIC positions and 3 closed out — a net gain of 5 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $188K. The largest seller was Stonepine Capital Management, cutting an estimated $2.5M.

  • 43 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2020, up from 38 in Q1 2020.
  • Funds reported $40M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2020, up 19% quarter-over-quarter.
  • 8 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2020 and 3 closed out, a net change of +5 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2020 was BlackRock, an estimated $188K added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2020 was Stonepine Capital Management, an estimated $2.5M sold.

Based on aggregated 13F filings for Q2 2020.